MEMBRANOUS LUPUS NEPHROPATHY

三种免疫抑制剂的疗效和毒性 对膜性狼疮患者的治疗方案进行评估 在12个月的研究期内发生肾病。肾脏的详细检查 肾功能、肾小球通透性与肾活检 形态学将在开始和结束时进行 治疗。系统性红斑狼疮患者， 肾病范围蛋白尿和活检证实为膜性 肾病将使用隔日强的松和将 随机接受：a)不接受额外治疗(对照组 组)，b)静脉脉冲环磷酰胺，最高1.0g/次 平方米的身体表面积，每隔一个月共6平方米 剂量，或c)口服环孢素A，每平方米最多200毫克 每天的体表面积总计为11个月。狼疮性疾病 将监测活动、肾功能测试和药物毒性 非常接近。分析将包括对 肾小球功能和病理的良好结果 随着药物相关毒性出现在每个治疗组的 为期12个月的学习结束。

The efficacy and toxicity of three immunosuppressive drug regimens will be evaluated in patients with membranous lupus nephropathy over a 12 month study period. Detailed tests of renal function, glomerular permselectivity and kidney biopsy morphology will be conducted at the beginning and end of treatment. Patients with systemic lupus erythematosus, nephrotic range proteinuria and biopsy documented membranous nephropathy will be treated with alternate day prednisone and will be randomized to receive: a) no additional therapy (control group), b) intravenous pulse cyclophosphamide up to 1.0 gram per square meter body surface area every other month for 6 total doses, or c) oral cyclosporin A up to 200 mg per square meter body surface area daily for a total of 11 months. Lupus disease activity, renal function tests and drug toxicities will be monitored closely. Analysis will include comparison of the number of favorable outcomes of glomerular function and pathology as well as drug-related toxicities appearing in each treatment group at the end of 12 months of study.